Acne Drugs: Medications That Cause or Treat Breakouts

How Acne Forms and Why Drugs Can Tip the Balance

Acne starts when four processes converge: excess sebum production, follicular hyperkeratinization, colonization by Cutibacterium acnes, and inflammation. Any medication that amplifies one of these pathways can provoke or worsen breakouts [1].

Androgens are the primary hormonal driver. They bind receptors on sebaceous glands, enlarge them, and increase sebum output. This is why testosterone replacement therapy (TRT) and anabolic steroids so reliably cause acne in both sexes. The American Academy of Dermatology (AAD) 2024 guidelines note that "drug-induced acne should be considered in any patient presenting with new-onset or worsening acne after starting a new medication" [2].

Conversely, drugs that reduce androgen signaling, limit C. acnes growth, or normalize keratinization form the backbone of acne therapeutics. The treatment ladder runs from topical retinoids and benzoyl peroxide for mild disease up through oral isotretinoin for severe nodulocystic acne. Between those poles sit antibiotics, hormonal agents, and newer fixed-dose combinations [3].

Understanding both sides of the drug-acne equation matters. A patient on lithium who develops sudden papulopustular eruptions does not need aggressive acne therapy. They need a medication review. A woman with post-adolescent jawline acne, on the other hand, may respond better to spironolactone than to another round of doxycycline.

Topical Treatments: First-Line Options for Mild to Moderate Acne

Topical retinoids and benzoyl peroxide, alone or in fixed-dose combination, are the recommended starting point for most acne patients [2].

Tretinoin (0.025% to 0.1% cream or gel) normalizes follicular keratinization and has over 50 years of clinical evidence. A 2019 Cochrane review of 34 trials (N=4,890) found that topical retinoids reduced inflammatory lesions by a mean of 14 lesions compared to vehicle at 12 weeks [4]. Adapalene 0.1% gel is available OTC in the United States and causes less irritation than tretinoin, making it a practical entry point for patients new to retinoid therapy.

Benzoyl peroxide (2.5% to 10%) is bactericidal against C. acnes through oxidative damage. It does not induce bacterial resistance, which is why the AAD recommends it as a companion to any antibiotic-containing regimen [2]. A concentration of 2.5% achieves similar efficacy to 10% with significantly less dryness and peeling [5].

Fixed-dose combinations pair these actives with antibiotics or each other. Adapalene 0.3%/benzoyl peroxide 2.5% (Epiduo Forte) and tretinoin 0.1%/benzoyl peroxide 3% (Twyneo) both showed superior lesion reduction compared to their individual components in phase 3 trials [3]. The newer clindamycin 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% triple combination (Cabtreo) received FDA approval in 2024, producing a 71.5% mean reduction in inflammatory lesions at week 12 [6].

Topical dapsone 7.5% gel is an underused option for adult female acne. In two pooled phase 3 trials (N=2,238), dapsone gel reduced inflammatory lesions by 48.9% versus 43.2% for vehicle at 12 weeks, with the greatest benefit seen in women over 25 [7].

Oral Antibiotics: Effective but Time-Limited

Oral antibiotics target C. acnes and suppress inflammation. They work. But they should not be used indefinitely.

Doxycycline (50 to 100 mg daily) and minocycline (50 to 100 mg daily) are the most commonly prescribed oral antibiotics for moderate inflammatory acne. A 2012 Cochrane review of 52 RCTs confirmed that tetracyclines reduce acne lesions significantly compared to placebo, with no consistent superiority among tetracycline subtypes [8]. Minocycline carries a rare but real risk of drug-induced lupus and hyperpigmentation with prolonged use.

The AAD recommends limiting oral antibiotic courses to 3 months and always co-prescribing benzoyl peroxide to reduce resistance selection [2]. Dr. Andrea Zaenglein, lead author of the AAD guidelines, has stated: "We have moved away from maintenance antibiotic therapy for acne. The evidence for resistance is too strong to ignore" [2].

Sarecycline, a narrow-spectrum tetracycline FDA-approved in 2018 specifically for acne, showed a 51.6% reduction in inflammatory lesions versus 35.3% for placebo at 12 weeks in the key SC1401 trial (N=483) [9]. Its narrower antibacterial spectrum may cause fewer gastrointestinal side effects, though long-term resistance data are still emerging.

Sub-antimicrobial-dose doxycycline (40 mg modified-release, marketed as Oracea) offers anti-inflammatory benefits without reaching bactericidal concentrations, theoretically limiting resistance pressure. This is an off-label but evidence-supported strategy [10].

Isotretinoin: The Closest Thing to a Cure

Isotretinoin remains the single most effective acne treatment. It addresses all four pathogenetic factors simultaneously.

Standard dosing targets a cumulative dose of 120 to 150 mg/kg over 15 to 20 weeks. A landmark meta-analysis of 30 studies (N=1,574) found complete clearance in 85% of patients after one course, with relapse rates of roughly 20% at 5 years [11]. Lower-dose protocols (0.25 to 0.5 mg/kg/day) are increasingly used for moderate acne, trading slightly higher relapse rates for fewer side effects [12].

The iPLEDGE program governs isotretinoin prescribing in the U.S. due to its category X teratogenicity. Two negative pregnancy tests, two forms of contraception, and monthly check-ins are mandatory for patients who can become pregnant. Monitoring should include baseline and periodic lipid panels and liver function tests, though the 2024 AAD update notes that monthly lab monitoring in otherwise healthy patients may be unnecessary [2].

Common side effects include xerosis (extremely dry skin and lips in over 90% of patients), epistaxis, myalgias, and elevated triglycerides. The purported link to inflammatory bowel disease has been largely refuted. A 2014 JAMA Dermatology meta-analysis (N=8.2 million) found no significant association between isotretinoin and IBD [13]. The depression and suicidality signal remains debated, but large epidemiologic studies have not confirmed a causal link, and several have shown improved mood scores after acne clearance [14].

Hormonal Agents: Targeting the Androgen-Sebum Axis

Hormonal therapy is a cornerstone for women with acne that clusters along the jawline, flares with menses, or resists standard topical and antibiotic therapy.

Spironolactone (50 to 200 mg/day) is an aldosterone antagonist that also blocks androgen receptors. It is not FDA-approved for acne but is widely used off-label. A 2020 retrospective cohort study (N=6,684) published in the BMJ found that spironolactone was associated with a 35% lower rate of antibiotic prescriptions for acne over 12 months compared to patients who continued antibiotics alone [15]. Typical response takes 3 to 6 months. Serum potassium monitoring is recommended at baseline and at 4 to 8 weeks, though the AAD notes that the risk of clinically significant hyperkalemia in young, healthy women is very low [2].

Combined oral contraceptives (COCs) suppress ovarian androgen production and increase sex hormone-binding globulin, reducing free testosterone. Four COC formulations are FDA-approved for acne: ethinyl estradiol/norgestimate (Ortho Tri-Cyclen), ethinyl estradiol/norethindrone acetate/ferrous fumarate (Estrostep Fe), ethinyl estradiol/drospirenone (Yaz), and ethinyl estradiol/drospirenone/levomefolate (Beyaz). A Cochrane review of 31 trials (N=12,579) showed that all COCs reduced both inflammatory and non-inflammatory lesions compared to placebo, with no clear superiority among formulations [16].

COCs containing drospirenone carry a modestly increased risk of venous thromboembolism compared to levonorgestrel-containing pills. Risk assessment should include smoking status, BMI, and personal or family history of clotting disorders.

Drugs That Cause or Worsen Acne

Drug-induced acne (sometimes called acneiform eruption) tends to present as monomorphous papulopustules without comedones, often appearing suddenly after medication initiation.

Corticosteroids are the most common culprits. Both systemic and high-potency topical steroids trigger "steroid acne," a folliculitis-like eruption on the trunk and proximal extremities. Prednisone doses above 20 mg/day frequently provoke it within 2 weeks. The mechanism involves immune suppression that permits Malassezia and C. acnes overgrowth, combined with direct stimulation of the pilosebaceous unit [17].

Testosterone and anabolic steroids predictably cause acne by flooding androgen receptors on sebaceous glands. Among men on TRT, acne incidence ranges from 15% to 40%, dose-dependent and more common with injectable formulations than with transdermal gels [18]. Women receiving testosterone for hypoactive sexual desire disorder also report acne at rates above 10%.

Lithium causes or worsens acne in roughly 30% to 45% of patients, typically within the first few months of treatment. The mechanism likely involves increased neutrophil activity and altered follicular keratinization [17].

Other documented offenders include phenytoin, isoniazid, cyclosporine, EGFR inhibitors (cetuximab, erlotinib), B vitamins (particularly B6 and B12 in high doses), and progestins with androgenic activity (levonorgestrel, norethindrone). The EGFR-inhibitor rash is technically a papulopustular eruption rather than true acne, but patients experience it similarly. It affects over 50% of patients on cetuximab and often requires dermatologic co-management [19].

A practical clinical pearl: if a patient develops acne-like lesions that are monomorphous, lack comedones, and start abruptly after a new medication, suspect drug-induced acneiform eruption rather than acne vulgaris. Treatment involves discontinuing or substituting the offending agent when possible.

Newer and Emerging Therapies

Several novel mechanisms have entered or are nearing the acne treatment pipeline.

Clascoterone 1% cream (Winlevi), FDA-approved in 2020, is the first topical antiandrogen approved for acne in both men and women. It blocks androgen receptors directly in the skin without systemic antiandrogenic effects. Two phase 3 trials (N=1,440) showed a 17.6% absolute success rate (IGA 0 or 1 with a 2-grade improvement) versus 7% for vehicle at 12 weeks [20]. The effect size is modest, but systemic safety makes it an attractive option for male patients and women who cannot take spironolactone or COCs.

Sarecycline and minocycline extended-release represent optimized oral antibiotic approaches designed to reduce off-target microbiome disruption.

Fixed-dose triple combinations (clindamycin/adapalene/benzoyl peroxide) compress three mechanisms into a single daily application, improving adherence. The Cabtreo approval data showed that 50.4% of patients achieved treatment success (IGA 0/1) at week 12, compared to 24.9% to 40.1% for the dual-component arms [6].

Anti-IL-17 and anti-IL-1 biologics are under investigation for severe, refractory acne, though none have reached phase 3. Case reports of secukinumab for hidradenitis suppurativa-associated acne have been published, but prospective data are needed [21].

Building a Treatment Ladder: Mild to Severe

Treatment selection follows disease severity, patient sex, pregnancy potential, and prior treatment history.

Mild comedonal acne responds to topical retinoid monotherapy. Adapalene 0.1% gel applied nightly is a reasonable starting point, with benzoyl peroxide wash in the morning for patients with mixed comedonal-inflammatory lesions [2].

Mild to moderate inflammatory acne benefits from fixed-dose topical combinations: adapalene/benzoyl peroxide or tretinoin/benzoyl peroxide. Adding a topical antibiotic (clindamycin) is reasonable but only in combination with benzoyl peroxide, never alone [2].

Moderate to severe inflammatory acne warrants the addition of an oral antibiotic (doxycycline 100 mg daily) for a maximum of 3 months while topical therapy takes hold. In women, spironolactone 50 to 100 mg daily or a COC may replace or follow the antibiotic course.

Severe nodulocystic acne that scars or fails two adequate courses of combination therapy is an indication for isotretinoin. Delay increases scarring risk. The 2024 AAD guidelines suggest that clinicians "should not reserve isotretinoin only as a last resort" when scarring is already present [2].

Drug-induced acneiform eruptions require addressing the causative medication. If the drug cannot be stopped (e.g., lithium for bipolar disorder), topical retinoids and benzoyl peroxide are first-line for symptomatic management. Oral doxycycline can be added for extensive involvement.

Patients receiving EGFR inhibitors present a special case: the severity of their rash correlates with better tumor response. The Oncology Nursing Society recommends prophylactic doxycycline 100 mg daily starting with EGFR-inhibitor therapy to reduce rash severity by approximately 50% without compromising antitumor efficacy [19].

Monitoring and When to Refer

Most acne is managed in primary care. Referral to dermatology is indicated for nodulocystic disease, scarring, suspected drug-induced eruptions that do not respond to medication adjustment, or when isotretinoin is being considered.

For patients on isotretinoin, baseline labs should include a complete blood count, lipid panel, hepatic function, and a pregnancy test for those who can become pregnant. Repeat lipids and liver function at 4 to 8 weeks. If values remain normal, some dermatologists now forgo additional lab draws unless the patient has risk factors [2].

For spironolactone, check a baseline metabolic panel. In healthy women under 45 with normal renal function, ongoing potassium monitoring may be unnecessary per recent observational data [15]. Women should be counseled that spironolactone is teratogenic (feminization of a male fetus) and contraception is required.

Patients on long-term doxycycline should be advised about photosensitivity, esophageal irritation (take with a full glass of water, upright for 30 minutes), and the rare risk of intracranial hypertension, particularly if co-prescribed isotretinoin (this combination is contraindicated).